Lupin gets USFDA nod for generic potassium deficiency drug
Company's subsidiary Gavis Pharmaceuticals has received final approval from USFDA to market potassium chloride extended release capsules
 "An employee of Lupin Limited works at a reception at their headquarters in Mumbai")
An employee of Lupin Limited works at a reception at their headquarters in Mumbai
Drug firm Lupin on Wednesday said its subsidiary Gavis Pharmaceuticals has received final approval from the US health regulator to market potassium chloride extended release capsules, used for treating potassium deficiency in the bloodstream, in the American market.
US-based Gavis has received final approval from US Food and Drug Administration (USFDA) to market a generic equivalent of Actavis Labs FL Inc's potassium chloride extended release capsules in various strengths, Lupin Ltd said in a regulatory filing.
Lupin had announced acquisition of Somerset-based Gavis Pharmaceuticals on July 23 last year.
According to IMS MAT June sales data, potassium chloride extended-release capsules had US sales of $75.4 million.
Lupin stock closed at Rs 1,595.30, up 0.36%, on BSE.
Don't miss the most important news and views of the day. Get them on our Telegram channel
First Published: Aug 17 2016 | 4:56 PM IST